SERVING OVERLOOKED PATIENTS
Live / Registered — Registered (as of 24 Mar 2026)
What this means for you
Registered since 24 Mar 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97388326
- Registration number
- 8187953
- Mark type
- Stylized text
- Filed
- 29 Apr 2022
- Published for opposition
- 21 Feb 2023
- Registered
- 24 Mar 2026
- Attorney of record
- Douglas R. Wolf
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders
Owner
- Azurity Pharmaceuticals, Inc., Woburn, MA, US
- Azurity Pharmaceuticals, Inc., Woburn, MA, US
- Azurity Pharmaceuticals, Inc., Woburn, MA, US
Prosecution history
- 24 Mar 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Mar 2026 — REGISTERED-PRINCIPAL REGISTER
- 28 Feb 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 28 Feb 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 17 Feb 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 04 Apr 2025 — USE AMENDMENT FILED
- 22 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Jul 2025 — SOU EXTENSION 4 GRANTED
- 03 Apr 2025 — SOU EXTENSION 4 FILED
- 21 Jul 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Feb 2025 — TEAS STATEMENT OF USE RECEIVED
- 16 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Oct 2024 — SOU EXTENSION 3 GRANTED
- 16 Oct 2024 — SOU EXTENSION 3 FILED